8-K - INM - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

of

the Securities Exchange Act of 1934

Dateof Report (Date of earliest event reported): September 5, 2025

INMED PHARMACEUTICALS INC.

(ExactName of Company as Specified in Charter)

British Columbia	001-39685	98-1428279
(Stateor Other Jurisdictionof Incorporation)	(Commission File Number)	(IRSEmployerIdentification No.)
InMed Pharmaceuticals Inc.<br><br> <br>Suite 1445 - 885 W. Georgia Street,<br><br> <br>Vancouver, B.C.<br><br> <br>Canada	V6C 3E8
---	---
(Address of Principal Executive Offices)	(Zip Code)

Company’s

telephone number, including area code: (604) 669-7207

Not

applicable

(FormerName or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written<br>communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
☐	Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
☐	Pre-commencement<br>communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	INM	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item7.01 Regulation FD Disclosure.

On September 5, 2025, the Company announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York. During the conference, members of InMed’s management team will also be conducting one-on-one meetings with investors. Additionally, a corporate presentation from the Company will be available online.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.	Description
99.1	News release, dated September 5, 2025
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED<br> PHARMACEUTICALS INC.
Date:<br> September 5, 2025	By:	/s/<br> Eric A Adams
		Eric<br> A Adams
		President<br> & CEO

Exhibit 99.1

NASDAQ: INM<br><br> <br>****<br><br> <br>1445 – 885 West Georgia St.<br><br> <br>Vancouver, BC, Canada V6C 3E8<br><br> <br>Tel: +1.604.669.7207<br><br> <br>Email: info@inmedpharma.com<br><br> <br>www.inmedpharma.com

InMed to Participate in the H.C. Wainwright 27th Annual GlobalInvestment Conference

Vancouver, British Columbia – September 05, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York. During the conference, members of InMed’s management team will also be conducting one-on-one meetings with investors. Additionally, a corporate presentation from the Company will be available online.

In the presentation, Mr. Michael Woudenberg, InMed’s Chief Operating Officer, will highlight updates and progress of InMed’s pipeline including recent data from the Company’s leading pharmaceutical program INM-901, in the treatment of Alzheimer’s, that was recently presented at Alzheimer’s AssociationInternational Conference (AAIC) 2025, the world’s leading forum for Alzheimer’s disease and dementia research.

H.C. Wainwright 27th Annual Global Investment ConferencePresentation Link: https://journey.ct.events/view/09f2e465-e7f2-45b7-83d6-e1fb4303ebc4

The webcast will be available for 90 days at the link above or on the InMed Investor Relations Events page: https://www.inmedpharma.com/investors/events/

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: a corporate presentation highlighting recent updates and progress with InMed’s pipeline including recent data from the Company’s lead program INM-901 in the treatment of Alzheimer’s

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.